1. Home
  2. ELTX vs KINS Comparison

ELTX vs KINS Comparison

Compare ELTX & KINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$9.91

Market Cap

185.4M

Sector

Health Care

ML Signal

HOLD

KINS

Kingstone Companies Inc.

HOLD

Current Price

$15.54

Market Cap

205.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELTX
KINS
Founded
2011
1886
Country
United States
United States
Employees
33
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
185.4M
205.7M
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
ELTX
KINS
Price
$9.91
$15.54
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$18.00
N/A
AVG Volume (30 Days)
112.2K
133.2K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
1.18%
EPS Growth
39.29
94.59
EPS
N/A
2.88
Revenue
$2,301,000.00
$214,867,301.00
Revenue This Year
N/A
$24.23
Revenue Next Year
N/A
$18.05
P/E Ratio
N/A
$5.61
Revenue Growth
N/A
38.50
52 Week Low
$5.80
$13.08
52 Week High
$14.93
$19.42

Technical Indicators

Market Signals
Indicator
ELTX
KINS
Relative Strength Index (RSI) 38.27 42.66
Support Level $8.76 $14.13
Resistance Level $10.16 $17.06
Average True Range (ATR) 0.75 0.76
MACD -0.19 -0.23
Stochastic Oscillator 2.14 9.20

Price Performance

Historical Comparison
ELTX
KINS

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

About KINS Kingstone Companies Inc.

Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.

Share on Social Networks: